Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.52 |
| ▸ | MME | P08473 | 7/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 7/20 | 0.50 |
| ▸ | ACE | P12821 | 6/20 | 0.50 |
| ▸ | CPA1 | P15085 | 5/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974284 | 1.00 | ITGB1 (0.52) | ITGB1ITGA4MMEACE2ACE | |
| SCHEMBL3972847 | 0.89 | HDAC1 (0.55) | — | |
| SCHEMBL6618300 | 0.88 | ITGB1 (0.54) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL3993538 | 0.86 | ITGA4 (0.46) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL5927344 | 0.86 | ITGB2 (0.62) | ITGB1ITGA4MMEACE2ACE | |
| SCHEMBL5926656 | 0.86 | MME (0.50) | ITGB1ITGA4MMEACE2ACE | |
| SCHEMBL5926681 | 0.86 | ERAP1 (0.53) | ITGB1ITGA4MMEACE2ACE | |
| SCHEMBL5926994 | 0.82 | KIFC1 (0.62) | ITGB1ITGA4POLB | |
| SCHEMBL4831380 | 0.81 | KIFC1 (0.64) | POLB | |
| SCHEMBL4831384 | 0.81 | KIFC1 (0.64) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | ITGB1 139/4885ITGA4 171/4885MME 1231/4885 |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | ITGB1 1520/4885ITGA4 1777/4885MME 1687/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ITGB1 240/4885ITGA4 312/4885MME 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.